Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.
| Current Price | ₹24.35 |
|---|---|
| Market Cap | ₹1,427 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 45 |
| Return on Equity | 11.42% |
| 52-Week Range | ₹10.37 – ₹37.24 |
| Beta (1Y) | 0.38 |
| Revenue | ₹88 Cr |
|---|---|
| Net Profit | ₹8 Cr |
| EPS (Basic) | ₹0.16 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Manufacturing and Sale of Active Pharmaceutical Ingredients (APIs)-100%
ANLON HEALTHCARE LIMITED is trading at ₹24.35, with a market capitalisation of ₹1,427 Cr.
ANLON HEALTHCARE LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
ANLON HEALTHCARE LIMITED has a P/E of 45 and a return on equity of 11.42%.
In Q1 FY27, ANLON HEALTHCARE LIMITED reported revenue of ₹88 Cr and net profit of ₹8 Cr, with basic EPS of ₹0.16 (consolidated, parsed from the company's exchange filing).